论文部分内容阅读
原发性肝癌(primary liver carcinoma,PLC)是全世界最常见的恶性肿瘤之一,在全球癌症死亡率中居第三位[1]。据世界卫生组织2008年数据显示,全世界新发肝癌估计748 000例,死亡病例大约696 000人[2]。而我国肝癌年发病人数约35万,每年约有32万人死于此病,发病率和病死率均占肿瘤中的第二位[3]。虽然目前新的介入、放化疗等对不能手术的PLC患者有一定疗效,但早期施行手术仍是目前首选的、最有效的治疗方法[4]。但是由于PLC起病隐
Primary liver carcinoma (PLC) is one of the most common malignancies in the world and ranks third in the global cancer death rate [1]. According to the WHO data in 2008, an estimated 748,000 new liver cancer cases worldwide, with about 696,000 deaths [2]. The annual incidence of liver cancer in China is about 350,000, about 32 million people die each year from the disease, morbidity and mortality rates accounted for the second in the tumor [3]. Although the new intervention, radiotherapy and chemotherapy for patients with PLC can not have a certain effect, but the early implementation of surgery is still the preferred, the most effective treatment [4]. However, due to PLC onset is hidden